TY  - JOUR
AU  - Prat, Aleix
AU  - Galván, Patricia
AU  - Jimenez, Begoña
AU  - Buckingham, Wesley
AU  - Jeiranian, H Arthur
AU  - Schaper, Carl
AU  - Vidal, Maria
AU  - Álvarez, Martina
AU  - Díaz, Sherley
AU  - Ellis, Catherine
AU  - Nuciforo, Paolo
AU  - Ferree, Sean
AU  - Ribelles, Nuria
AU  - Adamo, Barbara
AU  - Ramón Y Cajal, Santiago
AU  - Peg, Vicente
AU  - Alba, Emilio
PY  - 2015
DO  - 10.1158/1078-0432.CCR-15-0630
UR  - http://hdl.handle.net/10668/9950
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - Most hormone receptor (HR)(+)/HER2(-) breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those patients who are likely to benefit. Using the Prosigna assay, we first evaluated the...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Biopsy, Large-Core Needle
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Neoadjuvant Therapy
KW  - Neoplasm Grading
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Precision Medicine
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Reproducibility of Results
KW  - Treatment Outcome
KW  - Tumor Burden
TI  - Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
TY  - research article
VL  - 22
ER  -